NASDAQ:APREAprea Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aprea Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.56 -1.82 (-5.99 %) (As of 08/11/2020 03:39 PM ET) Add Compare Share Today's Range$28.56Now: $28.56▼$29.5850-Day Range$25.67MA: $31.62▼$39.5752-Week Range$15.10Now: $28.56▼$53.11Volume3,546 shsAverage Volume82,384 shsMarket Capitalization$601.47 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.2 Analyst's Opinion Consensus RatingAprea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.80, Aprea Therapeutics has a potential upside of 24.6% from its current price of $28.74.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesAprea Therapeutics has received 21 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAprea Therapeutics has received 28 “underperform” votes. (Add your “underperform” vote.)Community SentimentAprea Therapeutics has received 57.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aprea Therapeutics and other stocks. Vote “Outperform” if you believe APRE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APRE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,021,300.00 in company stock.Percentage Held by Insiders52.20% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.84% of the stock of Aprea Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aprea Therapeutics are expected to decrease in the coming year, from ($2.39) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.26 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APRE Previous Symbol CUSIPN/A CIKN/A Webwww.aprea.com Phone609-510-4718Debt Debt-to-Equity RatioN/A Current Ratio10.79 Quick Ratio10.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.92 per share Price / Book4.82Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares21,060,000Market Cap$601.47 million Next Earnings Date8/21/2020 (Estimated) OptionableNot Optionable $28.56 -1.82 (-5.99 %) (As of 08/11/2020 03:39 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive APRE News and Ratings via Email Sign-up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Aprea Therapeutics (NASDAQ:APRE) Frequently Asked Questions How has Aprea Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Aprea Therapeutics' stock was trading at $32.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APRE shares have decreased by 12.2% and is now trading at $28.56. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Aprea Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aprea Therapeutics. When is Aprea Therapeutics' next earnings date? Aprea Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Aprea Therapeutics. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics (NASDAQ:APRE) released its quarterly earnings data on Friday, May, 15th. The company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.12. View Aprea Therapeutics' earnings history. What price target have analysts set for APRE? 5 Wall Street analysts have issued 12-month target prices for Aprea Therapeutics' stock. Their forecasts range from $23.00 to $45.00. On average, they expect Aprea Therapeutics' stock price to reach $35.80 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price. View analysts' price targets for Aprea Therapeutics. Has Aprea Therapeutics been receiving favorable news coverage? Media stories about APRE stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aprea Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Aprea Therapeutics. Are investors shorting Aprea Therapeutics? Aprea Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 283,500 shares, an increase of 61.4% from the January 15th total of 175,700 shares. Based on an average daily volume of 115,200 shares, the short-interest ratio is presently 2.5 days. Currently, 2.8% of the shares of the company are short sold. View Aprea Therapeutics' Short Interest. Who are some of Aprea Therapeutics' key competitors? Some companies that are related to Aprea Therapeutics include Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), TG Therapeutics (TGTX), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), I-Mab (IMAB), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL) and Revance Therapeutics (RVNC). View all competitors. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Biogen (BIIB), Enbridge (ENB), Gilead Sciences (GILD), GlaxoSmithKline (GSK), ONEOK (OKE), Oyster Point Pharma (OYST), Pfizer (PFE), SpringWorks Therapeutics (SWTX) and Verizon Communications (VZ). Who are Aprea Therapeutics' key executives? Aprea Therapeutics' management team includes the following people: Mr. Christian S. Schade, Pres, CEO & Director (Age 58)Mr. Scott M. Coiante, Sr. VP & CFO (Age 52)Dr. Lars Abrahmsen, Sr. VP & Chief Scientific Officer (Age 61)Dr. Gregory A. Korbel, VP of Bus. Devel. (Age 43)Dr. Eyal C. Attar, Sr. VP & Chief Medical Officer (Age 49) When did Aprea Therapeutics IPO? (APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO. What is Aprea Therapeutics' stock symbol? Aprea Therapeutics trades on the NASDAQ under the ticker symbol "APRE." Who are Aprea Therapeutics' major shareholders? Aprea Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include 5AM Venture Management LLC (10.51%), Versant Venture Management LLC (8.81%), Candriam Luxembourg S.C.A. (0.62%), Alps Advisors Inc. (0.14%), Swiss National Bank (0.10%) and Virtus ETF Advisers LLC (0.05%). Company insiders that own Aprea Therapeutics stock include Christian S Schade, Johan Christenson, Kdev Investments Ab, Scott M Coiante, Scott M Rocklage, Vantage I LP Versant and Ventures Iv LP 5Am. View institutional ownership trends for Aprea Therapeutics. Which major investors are selling Aprea Therapeutics stock? APRE stock was sold by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Alps Advisors Inc., and UBS Group AG. Company insiders that have sold Aprea Therapeutics company stock in the last year include Kdev Investments Ab, Scott M Rocklage, and Ventures Iv LP 5Am. View insider buying and selling activity for Aprea Therapeutics. Which major investors are buying Aprea Therapeutics stock? APRE stock was bought by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Candriam Luxembourg S.C.A., Swiss National Bank, Virtus ETF Advisers LLC, New York State Common Retirement Fund, and PNC Financial Services Group Inc.. Company insiders that have bought Aprea Therapeutics stock in the last two years include Christian S Schade, Johan Christenson, Scott M Coiante, and Vantage I LP Versant. View insider buying and selling activity for Aprea Therapeutics. How do I buy shares of Aprea Therapeutics? Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aprea Therapeutics' stock price today? One share of APRE stock can currently be purchased for approximately $28.56. How big of a company is Aprea Therapeutics? Aprea Therapeutics has a market capitalization of $601.47 million. The company earns $-28,060,000.00 in net income (profit) each year or ($4.67) on an earnings per share basis. Aprea Therapeutics employs 14 workers across the globe. What is Aprea Therapeutics' official website? The official website for Aprea Therapeutics is www.aprea.com. How can I contact Aprea Therapeutics? Aprea Therapeutics' mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The company can be reached via phone at 609-510-4718 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
